KFDA approves two homegrown drugs
Published: 2011-08-22 06:58:00
Updated: 2011-08-22 06:58:00
Demonstrating the strength of the country's R&D capabilities, the Korea Food and Drug Administration Wednesday approved two Korean drugs – Shinpoong Pharmaceutical’s anti-malarial drug ‘Pyramax’ and JW Pharmaceutical’s Zepid (avanafil) for treatment of erectile dysfunction (ED).
Thus Korea bec...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.